Ublituximab not checked

TG Therapeutics, Inc. · TG-1101 · TG1101

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
8 active
28 in total · 7 in the EU
Targets
 

What this is

How it works
An antibody that marks B cells (a type of immune cell) for destruction. Used in blood cancers and autoimmune disease.CD20-directed Cytolytic Antibody FDA class
How it’s given
“Ublituximab (TG-1101) is a recombinant chimeric monoclonal antibody targeting CD20, available as a 25 mg/mL concentrate for intravenous use, supplied by TG Therapeutics, Inc.”In the company’s words, NCT04130997 on ClinicalTrials.gov
Tested for
Relapsing Multiple Sclerosis (3 trials), Relapsing Multiple Sclerosis (RMS), Multiple Sclerosis, Myasthenia Gravis, Schizophrenia
Main trialPhase 3
“The purpose of this study is to assess the pharmacokinetics of ublituximab when administered subcutaneously (SC) compared to intravenous (IV) administration in participants with RMS.”In the company’s words, NCT07211633 on ClinicalTrials.gov
Other names
TG-1101 · BRIUMVI · TG1101 · LFB-R603

Other drugs for Relapsing Multiple Sclerosis

All 54 drugs for Relapsing Multiple Sclerosis

Coming up6

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials28

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 31 Oct 2026 A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
Phase 3Recruiting 21 Jan 2027 Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Phase 3Active, not recruiting 31 May 2032 An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
Phase 2/3Recruiting 1 Jan 2030 Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
Phase 2Recruiting 31 Jul 2027 A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)
Phase 2Recruiting 1 Jul 2028 A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
Phase 2Recruiting 12 Dec 2028 Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
Phase 3Completed 1 Apr 2020 Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
Phase 3Completed 23 Jul 2020 Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )
Phase 3Completed 4 Aug 2020 Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)
Phase 3Terminated 22 Feb 2023 Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia
Phase 2/3Terminated 31 May 2022 Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Phase 2/3Terminated 20 Dec 2022 Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)
Phase 2Completed 27 Sep 2017 Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis
Phase 2Terminated 16 May 2022 Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma
Phase 2Terminated 22 May 2022 Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
Phase 2Terminated 25 May 2022 Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials
Phase 2Terminated 26 May 2022 A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304
Phase 2Completed 11 Nov 2022 An Extension of the TG1101-RMS201 Trial
Phase 1/2Completed May 2015 Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Phase 1/2Completed Dec 2015 Ublituximab + Ibrutinib in Select B-cell Malignancies
Phase 1/2Terminated 26 May 2022 Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL
Phase 1Terminated 7 Feb 2014 Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
Phase 1Completed 4 Nov 2021 Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
Phase 1Completed 21 Feb 2024 Study of TG-1801 in Subjects With B-Cell Lymphoma
Phase 1Terminated 21 May 2024 Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies
Phase 1Terminated 12 Jun 2024 Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Phase 1Authorised not given Pharmacokinetic/pharmacodynamic evaluation of ublituximab in patients with autoimmune diseases
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Ublituximab

Following is part of Solo: you see every change to Ublituximab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in